Neurometabolic Therapy for Parkinson's Disease

Parkinson's disease is characterized by a combination of motor and non-motor symptoms. One of the most common non-motor symptoms is asthenia, the prevalence of which in the structure of Parkinson's disease is 37.7-81.6%, depending on the stage. Due to the insufficient effectiveness of standard antiparkinsonian therapy for asthenia, it is advisable to study additional methods for correcting this condition. Our aim was to evaluate the clinical efficacy of the drug fonturacetam in patients with Parkinson's disease as an additional therapy for the correction of asthenic syndrome. A clinical comparative observation of 50 patients with Parkinson's disease of various stages and symptoms of asthenia was carried out. Patients were randomly assigned to 2 groups: the main group (n = 30), where in addition to basic antiparkinsonian therapy, fonturacetam was prescribed at a dose of 200 mg per day, divided into 2 doses; the control group (n = 20), where patients received only basic therapy. The course of therapy with fonturacetam was 30 days, the total duration of follow– up was 60 days. The effectiveness of treatment was assessed on the scales of asthenia MFI-20 (before (Visit 1), after treatment (Visit 2), 1 month after completion of treatment (Visit 3)); anxiety and depression HADS (Visits 1, 2); daytime sleepiness and the risk of sudden falling asleep Epworth (Visits 1, 2). In the main group, there was a distinct statistically significant effect of therapy after completion of the course (p = 0.00091), as well as in the follow–up period according to the MFI-20 scale (median values of the total score of 58 points, 48.5 and 50.5 at visits 1, 2, 3, respectively), while the most significant changes were observed in patients with Stage II according to Hoehn and Yahr, while an increase in asthenic symptoms was recorded in the control group. According to the HADS scale, there was a decrease in the severity of depression symptoms in the main group (the dynamics of scores was from 7 to 5, p = 0.01853); no such effect was observed in the control group. When assessing daytime sleepiness, patients of the main group noted a subjective improvement by visit 2, however, according to the Epworth scale, there were no statistical changes in both the main and control groups. The drug fonturacetam has significant antiasthenic and antidepressant effects in patients with Parkinson's disease, while the effect of therapy on the symptoms of asthenia is prolonged. Fonturacetam in a daily dose of 200 mg may be recommended for use in patients with Parkinson's disease as an adjunct to the main antiparkinsonian therapy.

1. Feigin V. L., et al. Global, regional, and national burden of neurological disorders, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016 // The Lancet Neurology. 2019; 18 (5): 459-480.

2. Krivonos O. V., Amosova N. A., Smolentseva I. G., Levin O. S. Epidemiology of Parkinson's disease. In: Guidelines for the diagnosis and treatment of Parkinson's disease / Pod red. Illarioshkina S. N., Levina O. S. 3-ye izd. M.: MEDpress-inform, 2019. S. 15-33.]

3. Tolosa E., Garrido A., Scholz S. W., Poewe W. Challenges in the diagnosis of Parkinson's disease // The Lancet. Neurology. 2021; 20 (5): 385-397. https://doi.org/10.1016/S1474-4422(21)00030-2.

4. Zhukova N. G., Zhukova I. A., Nikitina M. A. Objective methods for assessing non-motor manifestations in patients with Parkinson's disease. In: Parkinson's disease and movement disorders. A guide for physicians based on the materials of the IV National Congress on Parkinson's Disease and Movement Disorders (with international participation) / Pod red. S. N. Illarioshkina, O. S. Levina. 2017. S. 125-130.]

5. Zhukova I. A., Kolupayeva Ye. S., Zhukova N. G. Parkinson's disease and asthenic syndrome // Zhurnal nevrologii i psikhiatrii im. S. S. Korsakova. 2018; 118 (11): 60 63..]

6. Barone P., Antonini A., Colosimo C., Marconi R., Morgante L., Avarello T. P., Bottacchi E., et al. The PRIAMO study: A multicenter assessment of nonmotor symptoms and their impact on quality of life in Parkinson’s disease // Mov Disord. 2009; 24 (11):1641-1649. https://doi.org/10.1002/mds.22643.

7. Zhukova I. A., Gashilova F. F., Alifirova V. M. Cognitive and depressive disorders in Parkinson's disease // Sibirskiy konsilium. 2007; 5: 12-16.]

8. Smith C. R., Cullen B., Sheridan M.мP. Cognitive impairment in Parkinson's disease is multifactorial: a neuropsychological study // Acta Neurol Scand. 2020; 31. DOI: 10.1111/ane.13226.

9. Rocha R. S. B., De Oliveira Rocha L. S., Pena E. S. M. Analysis of autonomic modulation of heart rate in patients with Parkinson's disease and elderly individuals submitted to game therapy training // Geriatr Gerontol Int. 2018; 18 (1): 20-25. DOI: 10.1111/ggi.13130.

10. Grippo R. M., Güler R. M., Grippo A. D. Dopamine Signaling in Circadian Photoentrainment: Consequences of Desynchrony // Yale J Biol Med. 2019; 92 (2): 271-281.

11. Broen M. P., Leentjens A. F. G., Broen M. P., Hinkle J. T. Clinical Markers of Anxiety Subtypes in Parkinson Disease // J Geriatr Psychiatry Neurol. 2018; 31 (2): 55-62. DOI: 10.1177/0891988718757369.

12. Fodorova N. V., Yablonskaya A. Yu. Modern approaches to the correction of autonomic disorders in patients with Parkinson's disease // Ural'skiy med. zhurn. 2011; 2: 79-82.]

13. Sauerbier A., Coval I., Rosa-Grilo M. Treatment of Nonmotor Symptoms in Parkinson's Disease // Int Rev Neurobiol. 2017; 132: 361-379.

14. Jain S. Multi-organ autonomic dysfunction in Parkinson disease // Parkinsonism and Related Disorders. 2011; 17 (2): 77-83.

15. Rietdijk C. D., Perez-Pardo P., Garssen J. Exploring Braak's Hypothesis of Parkinson's Disease // Front Neurol. 2017; 13: 8-37. DOI: 10.3389/fneur.2017.00037.

16. Wakabayashi K., Mori F., Tanji K. Involvement of the peripheral nervous system in synucleinopathies, tauopathies and other neurodegenerative proteinopathies of the brain // Acta Neuropathol. 2010; 120: 1-12.

17. Sauerbiera A., et al. Nonmotor subtypes and Parkinson’s disease // Parkinsonism & Related Disorders. 2016; 1 (22): 41-46.

18. Chaudhuri K. R., et al. The nondeclaration of nonmotor symptoms of Parkinson’s disease to health care professionals: an international study using the nonmotor symptoms questionnaire // Mov Disord. 2010; 25 (6): 704-709.

19. Clinical guidelines "Parkinson's disease, secondary parkinsonism and other diseases manifested by parkinsonism syndrome": standards of patient management for physicians / Vserossiyskoye obshchestvo nevrologov i dr. M., 2022. Р. 301.]

20. Schifitto G., Friedman J. H., Oakes D., Shulman L., Comella C. L., Marek K., Fahn S.; Parkinson Study Group ELLDOPA Investigators. Fatigue in levodopa-naive subjects with Parkinson disease // Neurology. 2008; 71 (7): 481-485. https://doi.org/10.1212/01.wnl.0000324862.29733.69.

21. Hagell P., Brundin L. Towards an understanding of fatigue in Parkinson disease // J Neurol Neurosurg Psychiatry. 2009; 80 (5): 489-492. https://doi.org/10.1136/jnnp.2008.159772.

22. Spinazzi M., Casarin A., Pertegato V., Salviati L., Angelini C. Assessment of mitochondrial respiratory chain enzymatic activities on tissues and cultured cells // Nat Protoc. 2012; 7: 1235-1246. https://doi.org/10.1038/nprot.2012.058.

23. Karabanov A. V., Shvedkov V. V., Illarioshkin S. N. Experience in the use of Phenotropil in Parkinson's disease // Nervnyye bolezni. 2009; 4: 29-32.]

24. Akhapkina V. I., Fedin A. I, Avedisova A. S., Akhapkin R. V. The effectiveness of Phenotropil in the treatment of asthenic syndrome and chronic fatigue syndrome. Atmosphere // Nervnyye bolezni. 2004; 3: 28-32.]

25. Devlikamova F. I. Efficacy and safety of Actitropil in patients with asthenic syndrome: results of an observational clinical program // Nervnyye bolezni. 2022; 4: 8-18. https://doi.org/10.24412/2226-0757-2022-12819.]